58962-34-8

58962-34-8 structure

Name: 6-Oxoprostaglandin F1α
Chemical Name: 6-oxo-prostaglandin F1α
CAS Number: 58962-34-8
Molecular Formula: C₂₀H₃₄O₆
Molecular Weight: 370.480
Catalog: Research Areas Inflammation/Immunology
Create Date: 2018-04-16 08:00:00
Modify Date: 2024-01-04 15:07:51
6-keto Prostaglandin F1α is an endogenous metabolite present in Cerebrospinal_Fluid, Urine and Blood that can be used for the research of Meningitis, Rheumatoid Arthritis and Cardiopulmonary Resuscitation[1][2][3][4].

Name	6-oxo-prostaglandin F1α
Synonyms	Prost-13-en-1-oic acid, 9,11,15-trihydroxy-6-oxo-, (9α,11α,13E,15S)- 6-Oxoprostaglandin F1α 6-KETO-PROSTAGLANDIN F1ALPHA 6-OXO-9ALPHA,11ALPHA,15S-TRIHYDROXY-PROST-13E-EN-1-OIC ACID Prosta-13-en-1-oic acid, 9,11,15-trihydroxy-6-oxo-, (9α,11α,13E,15S)- 6-oxo-prostaglandin F1alpha 6-Oxoprostaglandin F1alpha 6-KETOPROSTAGLANDIN F1A (9α,11α,13E,15S)-9,11,15-Trihydroxy-6-oxoprost-13-en-1-oic acid 6-Keto Prostaglandin 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoic acid

Description	6-keto Prostaglandin F1α is an endogenous metabolite present in Cerebrospinal_Fluid, Urine and Blood that can be used for the research of Meningitis, Rheumatoid Arthritis and Cardiopulmonary Resuscitation[1][2][3][4].
Related Catalog	Research Areas >> Inflammation/Immunology
Target	Human Endogenous Metabolite
In Vitro	Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1].
References	[1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. [2]. Westcott JY, et al. Eicosanoids in human ventricular cerebrospinal fluid following severe brain injury. Prostaglandins. 1987 Dec;34(6):877-87. [3]. Laitinen O, et al. Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis. Clin Rheumatol. 1983 Dec;2(4):401-6. [4]. Strohmenger HU, et al. Concentrations of prolactin and prostaglandins during and after cardiopulmonary resuscitation. Crit Care Med. 1995 Aug;23(8):1347-55.

Safety Phrases	S22-S24/25
RIDADR	NONH for all modes of transport